Navigation Links
Lutonix Announces Achievement of Significant Milestones and Additions to Executive Leadership Team
Date:6/28/2011

MINNEAPOLIS, June 28, 2011 /PRNewswire/ -- Lutonix today announced receiving approval from the US Food and Drug Administration to begin enrollment in its LEVANT 2 IDE clinical trial for the treatment of peripheral arterial disease (PAD), along with receipt of CE Mark for its drug-coated balloon and ISO certification.  Lutonix is the first company to receive approval from the FDA to initiate a drug-coated balloon trial.  

The company also announced two new additions to its leadership team.  Shawn McCormick was named Chief Operating Officer and will oversee manufacturing, R&D, finance and administration for the company.  Leslie Trigg was named Executive Vice President, Marketing and Commercial Strategy and will oversee all commercialization aspects of the business.

LEVANT 2 Trial Set to Begin

LEVANT 2 is a global, multicenter, randomized study evaluating the safety and efficacy of the Moxy™ Drug Coated Balloon compared to a standard angioplasty balloon for treating diseased leg arteries above the knee.  The trial is designed to support an application to the US FDA for approval of the Moxy balloon.  Co-principal investigators for this international study are Dr. Ken Rosenfield (Massachusetts General Hospital, Boston MA) and Dr. Dierk Scheinert (University of Leipzig, Leipzig Germany).

The LEVANT 2 trial was preceded by LEVANT 1, a multi-center, prospective randomized trial of 101 patients with PAD.  In this study, the Moxy balloon was compared to standard angioplasty.  Data presented during the 2010 Transcatheter Cardiovascular Therapeutics meeting showed that the Moxy balloon had the ability to safely and substantially inhibit restenosis.

"Finding a durable treatment for PAD has proven to be one our most difficult clinical challenges," said Dr. Rosenfield.  "PAD patients are in great need of better treatment options.  This trial is an important step forward
'/>"/>

SOURCE Lutonix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lutonix Inc. Announces $20 Million Series B Financing
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  Boston Scientific Corporation (NYSE: ... announced agreement to purchase the Interventional business of ... Boston Scientific to offer physicians and healthcare systems ... challenging vascular conditions. The addition of ... technologies supports the Boston Scientific strategy to provide ...
(Date:9/2/2014)... DIEGO , Sept. 2, 2014  Volcano ... company focused on improving patient and economic outcomes ... innovative minimally invasive coronary and peripheral visualization, physiology ... be participating in the Morgan Stanley Healthcare conference ... by Scott Huennekens , president and chief ...
(Date:9/2/2014)... , Sept. 2, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... Food and Drug Administration (FDA) has granted orphan drug ... hypertension. "The FDA Office of Orphan ... from sponsors to identify and designate drug candidates that ... evaluation and development of such products," said Craig ...
Breaking Medicine Technology:Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 2Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 3Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 4Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 5Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 4
... SUNNYVALE, Calif., July 7, 2011 Cepheid (Nasdaq: ... for its 2011 second quarter ended June 30, 2011, on ... The company will host a management presentation at ... discuss the results.  To access the live webcast, please visit ...
... just three weeks after hearing oral argument, the First District ... judgment against Johnson & Johnson (NYSE: JNJ ) ... death case involving their Duragesic® fentanyl pain patch. ... in DiCosolo v. ALZA Corp, et al ., obtained ...
Cached Medicine Technology:Cepheid Schedules 2011 Second Quarter Financial Results Announcement and Webcast 2Heygood, Orr & Pearson: Court of Appeals Affirms $16.56 Million Judgment in Defective Fentanyl Patch Case 2Heygood, Orr & Pearson: Court of Appeals Affirms $16.56 Million Judgment in Defective Fentanyl Patch Case 3
(Date:9/2/2014)... September 02, 2014 The Dream2Walk Foundation along ... on Sept. 14th, 2014 during Spinal Cord Injury Awareness Month ... Lynn England, and Chuck Ligon. Linear Automotive will be there ... show. , Doors open at 2pm. The car show is ... one free pass to the concert. There will be trophies ...
(Date:9/2/2014)... Kathleen Doheny HealthDay ... The U.S. obesity epidemic is a driving force behind the ... study. Researchers looked at data from five national surveys ... increase in diabetes over time could be explained by factors ... U.S. adults. The investigators found that the prevalence of ...
(Date:9/2/2014)... By Steven Reinberg ... (HealthDay News) -- Stimulant medications -- such as Adderall, ... (ADHD) in children, won,t stunt their growth, a new ... final height as adults," said study researcher Dr. Slavica ... Clinic in Rochester, Minn. Katusic noted that results ...
(Date:9/2/2014)... HealthDay Reporter TUESDAY, Sept. 2, 2014 ... loss by blocking a certain nerve linked to appetite and ... patients. Using electric impulses to block the vagus nerve, ... suppress feelings of hunger. And, they did, just not to ... the nerve that connects the brain to the gut can ...
(Date:9/2/2014)... 2, 2014 (HealthDay News) -- Drinking and marijuana may ... a new study suggests. Researchers analyzed 2007 to ... school seniors who said they had used alcohol or ... drinking alcohol was associated with more unsafe driving, damage ... about actions while under the influence of alcohol, especially ...
Breaking Medicine News(10 mins):Health News:Gas Monkey Hosts Concert in Dallas Benefiting Dream2Walk Foundation with Linear Automotive 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 2Health News:Obesity Fueling Rise in Diabetes Rates, Study Finds 3Health News:ADHD Medications Won't Stunt Kids' Growth, Study Finds 2Health News:ADHD Medications Won't Stunt Kids' Growth, Study Finds 3Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 2Health News:Nerve Blocking Procedure Fails to Impress in Weight Loss Study 3Health News:Booze, Pot Bad for Teens in Different Ways, Study Suggests 2
... be making us hungrier, so we eat more, which in ... Yang and his colleagues at the Lawson Health Research Institute ... tissue can reproduce a hormone that stimulates fat cell production. ... way we think about and treat abdominal obesity. , Yang ...
... 16 Skanska USA Building Inc.,announced today that ... service the,growing Indiana construction markets. The announcement was ... Midwest operations., "Indiana is a strong construction ... "Skanska is an industry leader and after,working in ...
... Facing the ... Healthcare Industry, ... with U.S. News & World Report,hosted an exclusive panel discussion ... National Press Club in Washington, D.C.,The event, attended by Congressional ...
... with a faulty breast cancer gene could be at ... genes, according to research published this month in the ... University of Pennsylvania School of Medicine join an international ... 10,000 women carrying a BRCA1 or BRCA2 mutation for ...
... the source should lead to more effective vaccines, researchers say ... strains of virus that produce seasonal flu epidemics start in ... of the world, researchers report. , And by focusing on ... to improve their forecast of seasonal flu strains and develop ...
... Ala. - New clinical data showed some cancer patients ... AME-133v, said a researcher at the University of Alabama ... 15th during the 2008 annual meeting of the American ... 1 clinical trial data showed AME-133v had a potent ...
Cached Medicine News:Health News:Your belly fat could be making you hungrier 2Health News:Skanska Opens Indianapolis Office 2Health News:Siemens Addresses Cost vs. Value Issues In Healthcare and Technology 2Health News:Siemens Addresses Cost vs. Value Issues In Healthcare and Technology 3Health News:Breast cancer risk amplified by additional genes in combo with BRCA mutation 2Health News:Seasonal Flu Outbreaks Start in Asia: Study 2Health News:Seasonal Flu Outbreaks Start in Asia: Study 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: